Humira and Injection site mass - a phase IV clinical study of FDA data
We study 735,454 people who have side effects when taking Humira. Injection site mass is found, especially among people who are female, 60+ old, have been taking the drug for < 1 month, also take Methotrexate and have Psoriasis.
The phase IV clinical study analyzes which people take Humira and have Injection site mass. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
735,454 people reported to have side effects when taking Humira.
Among them, 1,746 people (0.24%) have Injection site mass.
What is Humira?
Humira has active ingredients of adalimumab. It is used in rheumatoid arthritis. Currently, eHealthMe is studying from 738,366 Humira users.
What is Injection site mass?
Injection site mass is found to be associated with 1,246 drugs and 746 conditions by eHealthMe. Currently, we are studying 34,616 people who have Injection site mass.
Number of Humira and Injection site mass reports submitted per year:
Time on Humira when people have Injection site mass *:
Gender of people who have Injection site mass when taking Humira*:
Age of people who have Injection site mass when taking Humira *:
Common drugs people take besides Humira *:
Common side effects people have besides Injection site mass *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Humira and have Injection site mass?Check whether Injection site mass is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Humira side effects by duration, gender and age:
- Humira side effects (738,366 reports)
Injection site mass treatments and more:
- Injection site mass (34,616 reports)
Common drugs associated with Injection site mass:
- Enbrel: 3,739 reports
- Bydureon: 2,752 reports
- Sandostatin: 2,210 reports
- Metformin: 2,046 reports
- Bydureon bcise: 1,965 reports
- Sandostatin lar: 1,828 reports
- Humira: 1,746 reports
- Vivitrol: 1,744 reports
- Copaxone: 1,342 reports
- Repatha: 1,340 reports
All the drugs that are associated with Injection site mass:
- Injection site mass (1,246 drugs)
Common conditions associated with Injection site mass:
- Type 2 diabetes: 3,658 reports
- Multiple sclerosis: 3,191 reports
- Rheumatoid arthritis: 2,849 reports
- High blood cholesterol: 1,488 reports
- Diabetes: 1,402 reports
All the conditions that are associated with Injection site mass:
- Injection site mass (746 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on adalimumab (the active ingredients of Humira) and Humira (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Bydureon and Hair Loss - 14 seconds ago
- Tylenol and Increased Activity - 17 seconds ago
- Mexiletine Hydrochloride and Voltaren drug interaction - 19 seconds ago
- Pletal and Eosinophilic Pneumonia - 27 seconds ago
- Valproic Acid and Weight Loss - 38 seconds ago
- Myambutol and Rashes - 39 seconds ago
- Uniphyl and Taxotere drug interaction - 40 seconds ago
- Klonopin and Drug Abuse And Dependence - 44 seconds ago
- Amlodipine Besylate and Basaglar drug interaction - 55 seconds ago
- Lisinopril and Reversible Ischaemic Neurological Deficit - 57 seconds ago